Premium
Priming in the brain, an immunologically privileged organ, elicits anti‐tumor immunity
Author(s) -
FathallahShaykh Hassan M.,
Gao Wei,
Cho Michael,
Herrera Maria Alejandra
Publication year - 1998
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/(sici)1097-0215(19980119)75:2<266::aid-ijc16>3.0.co;2-b
Subject(s) - immune system , immunology , glioma , cd8 , major histocompatibility complex , central nervous system , priming (agriculture) , biology , immunity , microglia , acquired immune system , immunization , cellular immunity , brain tumor , cancer research , medicine , pathology , neuroscience , inflammation , botany , germination
A crucial question in the study of tumor neuro‐immunology concerns the capacity of the central nervous system to initiate and execute an immune response. In a 100% fatal rat malignant glioma model, genetically modified tumors secreting INF‐γ intracerebrally generate an immune response resulting in a substantial increase in survival time, tumor rejection and specific systemic immunity. Tumors modified to secrete IL‐2 alone do not change the biologic behavior of transfected gliomas. INF‐γ induces elevated expression of major‐histocompatibility‐complex‐class‐I and ‐class‐II molecules in microglia throughout the brain and invokes enhanced tumor infiltration by CD4, CD8 and NK cells. These findings demonstrate successful immunization against a central‐nervous‐system tumor by direct priming in the brain with a live growth‐competent tumor vaccine. Int. J. Cancer 75:266–276, 1998. © 1998 Wiley‐Liss, Inc.